

24 January 2024



RESEARCH DELTA ADVISORS


US GENERICS – UPCOMING LOSS OF EXCLUSIVITIES: 2024-2026

☎ +91.9909919584

✉ nimish@researchdelta.com

US GENERICS – LOSS OF EXCLUSIVITIES: 2024-2026


LOE – 2024 THROUGH 2026



Source:- Para IV Insights (Research Delta)


SOLE FTFS DOMINATE UPCOMING PARA IVS

SALES BREAKUP AS PER NO OF FTFS




Source:- Para IV Insights (Research Delta)

SIMPLE GENERICS DOMINATES UPCOMING TWO YEARS



Source:- Para IV Insights (Research Delta)

INNOVATORS' EXPOSURE TO GENERICS



Source:- Para IV Insights (Research Delta)

GENERICS OPPORTUNITY – INDIAN CO. DOMINATES PARA IV SPACE

Sr. No.	Company	No. of Para IVs	No. of FTFs	FTFs as % Para IVs
1	Teva	30	20	67%
2	Lupin	27	17	63%
3	Zydus Cadila	27	13	48%
4	Apotex	26	14	54%
5	MSN Labs	22	12	55%
6	Sun Pharma	19	11	58%
7	Dr Reddy's	17	7	41%
8	Aurobindo	17	7	41%
9	Sandoz	17	9	53%
10	Actavis	16	13	81%
11	Mylan	15	11	73%
12	Alkem	11	7	64%
13	Watson	11	7	64%
14	Alembic	10	5	50%
15	Prinston Pharma	9	6	67%
16	Accord (Intas)	8	3	38%
17	Hetero	7	5	71%
18	Par Pharma	7	3	43%
19	Biocon	7	1	14%
20	Ajanta Pharma	7	2	29%
21	Amneal	7	3	43%
22	Macleods	6	3	50%
23	Torrent	6	4	67%
24	Annora Pharma	6	2	33%

Source:- Para IV Insights (Research Delta)

ANNEXURE

2024:LIST OF PRODUCTS LOSS OF EXCLUSIVITIES

Brand Name	Generic Name	Dosage
Gralise	Gabapentin	300, 600 mg; Tablet
Tasigna	NILOTINIB HYDROCHLORIDE MONOHYDRATE	150mg, 200mg Capsule oral
RESTASIS	CYCLOSPORINE	0.05% Emulsion:Ophthalmic
Qsymia	Phentermine Hydrochloride and Topiramate	(3.75/23,7.5/46,11.25/69,15/92)mg;Capsule Extended
Oxtellar XR	Oxcarbazepine	150, 300 mg; Tablet, Extended Release
Belviq	Lorcaserin Hydrochloride	10 mg; Tablet, Oral
Tirosint	Levothyroxine Sodium	75, 150 mcg; Capsule, Oral
VICTOZA	LIRAGLUTIDE RECOMBINANT	6mg/ml; Solution, Subcutaneous
Oxtellar XR	Oxcarbazepine	600 mg; Tablet, Extended Release
Tasigna	NILOTINIB HYDROCHLORIDE MONOHYDRATE	50 mg; Capsule
Vyzulta	Latanoprostene Bunod	0.024% ; Ophthalmic Solution
Myrbetriq	Mirabegron	25 mg; Tablet, Extended Release
Myrbetriq	Mirabegron	50 mg; Tablet, Extended Release
NASCOBAL	CYANOCOBALAMIN	0.5mg/Spray; Spary, Metered, Nasal
Sprycel	Dasatinib	20, 50, 70, 100 mg; Tablet
Sprycel	Dasatinib	80mg and 140mg; Tablet, Oral
Prolensa	BROMFENAC SODIUM	EQ 0.07% Acid; Solution/Drops, Ophthalmic
Stendra	Avanafil	50,100,200 mg; Tablet, Oral
Gattex Kit	Teduglutide	5mg/vial; Powder, Subcutaneous
Morphabond ER	Morphine Sulfate	15,30,60,100 mg; Tablet, Extended Release
BELEODAQ	BELINOSTAT	500mg/ vial; Powder, Intravenous
Vyndaqel	Tafamidis meglumine	20 mg; Capsules

Source:- Para IV Insights (Research Delta)

2024:LIST OF PRODUCTS LOSS OF EXCLUSIVITIES

Brand Name	Generic Name	Dosage
Ulesfia	Benzyl Alcohol	5% Lotion, Topical
SYNDROS	DRONABINOL	5 mg/ml; Solution, Oral
Ixempra Kit	Ixabepilone	15mg/vial and 45mg/vial; Injectable
Entresto	Sacubitril; Valsartan	24/26mg, 49/51mg, 97/103mg; Tablet, oral
FLOVENT HFA	FLUTICASONE PROPIONATE	0.044,0.11,0.22 mg/INH;Aerosol,Metered,Inhalation

Source:- Para IV Insights (Research Delta)

THANK YOU